Abstract 20252: Use of Ambulatory Event Monitoring in Identifying Patients With Delayed Presentation of High-Grade Atrioventricular Block Following Transcatheter Aortic Valve Replacement

    loading  Checking for direct PDF access through Ovid


Introduction: Delayed high-grade atrioventricular block (H-AVB) following transcatheter aortic valve replacement (TAVR) has been reported, but identification of such patients post-discharge (DC) has not been well studied. We assessed the utility of ambulatory event monitoring (AEM) in identifying such patients and risk factors.

Methods: Patients undergoing index TAVR at our institution from October 2016-May 2017 without a preexisting pacing device and without pre-discharge H-AVB necessitating permanent pacemaker (PPM) implantation were discharged with 30-day AEM. Baseline, procedural, and follow-up data were collected and compared among those with and without subsequent need for post-discharge PPM.

Results: Among 59 patients undergoing TAVR, 11 had prior PPM or ICD, and 6 required pre-DC PPM implant for H-AVB; 40 were discharged with 30-day AEM. Six (15%) developed H-AVB (3 Mobitz II 2nd degree AVB, 3 complete AVB) at a median (range) of 5 (4-24) days post-TAVR. There was no statistically significant difference in age, gender, or TAVR valve type between those with or without need for post-DC PPM, although 67% of the subjects presenting with late H-AVB had Edwards Sapien 3® valve, vs. 33% with Edwards Evolut® implanted (Figure, A). Presence of right bundle branch block (RBBB) at baseline was significantly associated with late H-AVB presentation (Figure, A). While 50% of subjects developed change from baseline AV conduction, this was not significantly associated with post-DC H-AVB (Figure, A). Those developing H-AVB on AEM were more likely to have RBBB or interventricular conduction delay after TAVR (Figure).

Conclusions: Delayed H-AVB occurred in 15% of our patients discharged after TAVR and was identified as late as 24 days post-discharge. Ambulatory monitoring of post-TAVR patient is warranted, especially among patients with baseline RBBB, but even among patients without significant conduction disease. Further study to identify risk factors is needed.

Related Topics

    loading  Loading Related Articles